for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bio-Rad Laboratories, Inc.

BIO

Latest Trade

726.74USD

Change

5.26(+0.73%)

Volume

15,066

Today's Range

715.15

 - 

728.05

52 Week Range

507.22

 - 

832.70

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
721.48
Open
721.87
Volume
15,066
3M AVG Volume
2.60
Today's High
728.05
Today's Low
715.15
52 Week High
832.70
52 Week Low
507.22
Shares Out (MIL)
29.77
Market Cap (MIL)
21,564.55
Forward P/E
49.94
Dividend (Yield %)
--

Next Event

Q3 2021 Bio Rad Laboratories Inc Earnings Release

Latest Developments

More

Bio-Rad Reports Q2 2021 Financial Results

Bio-Rad And 10X Genomics Announce Settlement To Resolve Multiple Litigations

10X Genomics Inc Says Entered Into A Global Settlement And Cross-License Agreement With Bio-Rad Laboratories, Inc

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets approximately 6,000 reagents, apparatus and laboratory instruments. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.

Industry

Scientific & Technical Instr.

Contact Info

1000 ALFRED NOBEL DR

HERCULES, CA

94547-1811

United States

+1.510.7247000

http://www.bio-rad.com/

Executive Leadership

Norman D. Schwartz

Chairman of the Board, President, Chief Executive Officer

Ilan Daskal

Chief Financial Officer, Executive Vice President

Andrew J. Last

Chief Operating Officer, Executive Vice President

Timothy Scott Ernst

Executive Vice President, General Counsel, Secretary

Michael Crowley

Executive Vice President - Global Commercial Operations

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

2.3K

2019

2.3K

2020

2.5K

2021(E)

2.8K
EPS (USD)

2018

5.840

2019

7.060

2020

10.520

2021(E)

14.448
Price To Earnings (TTM)
5.38
Price To Sales (TTM)
7.49
Price To Book (MRQ)
1.85
Price To Cash Flow (TTM)
5.16
Total Debt To Equity (MRQ)
0.11
LT Debt To Equity (MRQ)
0.09
Return on Investment (TTM)
34.14
Return on Equity (TTM)
32.09

Latest News

Latest News

Bio-Rad, 10x Genomics settle genomics patent war

Rivals Bio-Rad Laboratories Inc and 10x Genomics Inc have settled their multi-front battle over microfluidic genetic analysis technology, 10x announced Tuesday.

Bio-Rad, Harvard settle DNA analysis patent dispute with French company

Bio-Rad Laboratories has settled its patent infringement claims against French biotech company Stilla Technologies three days after the start of a trial in Boston federal court, according to a court filing.

Fed Circ affirms mixed ITC ruling in 10x and Bio-Rad's patent fight

The U.S. Court of Appeals for the Federal Circuit affirmed an International Trade Commission ruling Friday that some genetic-analysis products imported by 10x Genomics Inc infringe rival Bio-Rad Laboratories Inc's patents.

Federal Circuit affirms Bio-Rad infringed rival 10x Genomics' patents

The U.S. Court of Appeals for the Federal Circuit on Thursday upheld a ruling by the International Trade Commission that the importation and sale of Bio-Rad Laboratories Inc genetic-analysis products infringes patents owned by rival 10x Genomics Inc.

BRIEF-Bio Rad Laboratories Estimates Q2 Currency-Neutral Sales To Decline By 5% To 10%

* BIO RAD LABORATORIES SAYS IT EXPECTS Q2 2020 YEAR-OVER-YEAR CURRENCY NEUTRAL SALES MAY DECLINE BY 5 TO 10 PERCENT - SEC FILING Source text: (https://bit.ly/3glQfJ0) Further company coverage:

BRIEF-Bio-Rad Reports Q1 Non-GAAP Earnings Per Share $1.91

* Q1 EARNINGS PER SHARE ESTIMATE $1.57 -- REFINITIV IBES DATA

BRIEF-Bio-Rad Receives FDA Emergency Use Authorization For Droplet Digital Pcr Sars-Cov-2 Test Kit

* BIO-RAD RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR DROPLET DIGITAL PCR SARS-COV-2 TEST KIT Source text for Eikon: Further company coverage:

BRIEF-Bio-Rad Begins Shipping COVID-19 Antibody Test

* BIO-RAD BEGINS SHIPPING SARS-COV-2 (COVID-19) ANTIBODY TEST THAT OFFERS MORE THAN 99 PERCENT SPECIFICITY AND 98 PERCENT SENSITIVITY Source text for Eikon: Further company coverage:

BRIEF-Bio-Rad Acquires Celsee Inc

* BIO-RAD ACQUIRES CELSEE, INC., A SINGLE-CELL ANALYSIS SOLUTIONS PROVIDER

BRIEF-Bio-Rad To Launch Serology Assay To Detect Coronavirus Antibodies

* BIO-RAD ANNOUNCES THE LAUNCH OF A SEROLOGY ASSAY TO DETECT CORONAVIRUS (COVID-19) ANTIBODIES

BRIEF-Biodesix Partners With Bio-Rad To Bring Emergency Use Authorization Covid-19 Ddpcr Test To The U.S.

* BIODESIX PARTNERS WITH BIO-RAD TO BRING EMERGENCY USE AUTHORIZATION (EUA) COVID-19 DDPCR™ TEST TO THE U.S.

BRIEF-Bio-Rad Partners With Testing Labs Worldwide To Support Covid-19 Testing

* BIO-RAD PARTNERS WITH TESTING LABS WORLDWIDE TO SUPPORT COVID-19 TESTING Source text for Eikon: Further company coverage:

CORRECTED-(OFFICIAL)-BRIEF-Bio-Rad Posts Q2 EPS Of $19.86 (Aug. 1)

* Q2 SALES $572.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $566.2 MILLION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up